BANGKOK — Thailand has achieved a major medical breakthrough with the successful production of Imcranib 100, its first domestically developed targeted cancer therapy pill. The milestone, realized under the visionary leadership of Her Royal Highness Princess Chulabhorn Krom Phra Srisavangavadhana, marks a significant step forward in the nation’s ability to provide advanced, affordable cancer care.

Air Pollution Spurs Lung Cancer Spike in Northern Thailand

Developed at a royal-initiated pharmaceutical facility in Sattahip, Chon Buri, Imcranib 100 is a tyrosine kinase inhibitor (TKI) containing 100 milligrams of Imatinib, designed to precisely target cancer cells while minimizing damage to healthy tissue. Approved by Thailand’s Food and Drug Administration (FDA) on May 20, 2025, the drug is now available at Chulabhorn Hospital, offering a more affordable alternative to imported medications.

A Royal Vision for Medical Independence

The Chulabhorn Royal Academy (CRA), overseeing the project, emphasized that the drug’s development was driven by Princess Chulabhorn’s commitment to improving cancer treatment accessibility. The manufacturing plant, Thailand’s first GMDP PIC/s-certified cancer drug facility, ensures compliance with international quality standards, from raw material analysis to final production.

“This achievement not only reduces Thailand’s reliance on expensive imports but also strengthens our national pharmaceutical expertise,” the CRA stated.

Thailand has reached a historic milestone in public health with the domestic development of its first targeted oral cancer drugs, dramatically increasing treatment accessibility and reducing reliance on costly imports: https://t.co/1U0qeWWTQO pic.twitter.com/sGuWH0xmjM

— Thailand NOW (@ThailandNOW1) July 9, 2025

Expanding Treatment Options

Imcranib 100 is effective against several cancers, including:

• Chronic myeloid leukemia (CML)

• Philadelphia chromosome-positive acute leukemia

• Gastrointestinal stromal tumors (GIST)

• Dermatofibrosarcoma protuberans (DFSP, a rare skin cancer)

In another landmark development, the Chulabhorn Research Institute has also produced Herdara (Trastuzumab), Thailand’s first locally developed biologic cancer drug, also FDA-approved on May 20. Unlike traditional manufacturing, Herdara was developed entirely by Thai scientists without foreign technology transfer, showcasing the country’s growing biopharmaceutical independence.

Doctors from King Chulalongkorn Memorial Hospital Confirm ‘Lung Cancer’ is Curable with Correct Understanding, Early Detection, and Timely Treatment

A New Era for Thai Healthcare

This breakthrough promises more personalized, cost-effective cancer care for Thai patients while positioning Thailand as a regional leader in pharmaceutical innovation. The CRA highlighted that the success of Imcranib 100 and Herdara lays the foundation for future drug development, ensuring long-term medical security and improved public health outcomes.

-Thailand News (TN)